title: Effect of steatosis donor liver transplantation on hepatocellular carcinoma recurrence: experience at a single institution.
abstract: OBJECTIVE
  The increasing demand for transplantation has led application of steatotic liver as the graft. The aim of this study was to determine the effect of donor graft steatosis on overall outcome and tumor recurrence after liver transplantation for hepatocellular carcinoma.
  
  
  METHODS
  131 patients that underwent liver transplantation for hepatocellular carcinoma between 2007 and 2008 were included. Donor steatosis was categorized as non-steatosis group (0%-10%, n=101) and steatosis group (>10%, n=30). The Kaplan-Meier method and Cox proportional hazard regression model was used for data analysis.
  
  
  RESULTS
  Postoperative recipient survival rate was 81% and 66.6% at 1 and 3 years, respectively, for non-steatotic graft; 87.5% and 58.3% for mild steatosis; 83.3% and 41.7% for moderate to severe steatosis (p=0.303). Postoperative tumor recurrence rate was 15.8% and 28.7% at 1 and 3 years, respectively, for grafts with no steatosis; 8.3% and 20.8% for those with mild steatosis; 33.3% and 50% for those with moderate to severe steatosis, (p>0.05).
  
  
  CONCLUSIONS
  Steatotic donor was not associated with a worse prognosis in early stage postoperative and mild fatty liver did not increase tumor recurrence risks. The moderate to severe status of fatty liver had some effect on tumor recurrence.
authors.affiliation: Department of Transplantation, Tianjin Medical University, Tianjin, China.
authors.forename: Da Hong
authors.initials: da H
authors.lastname: Teng
authors.forename: Zhi Jun
authors.initials: ZJ
authors.lastname: Zhu
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
authors.forename: Yong Lin
authors.initials: YL
authors.lastname: Deng
authors.forename: Li Ying
authors.initials: LY
authors.lastname: Sun
authors.forename: Cheng
authors.initials: C
authors.lastname: Pan
authors.forename: Yi He
authors.initials: YH
authors.lastname: Liu
authors.forename: Hong Li
authors.initials: HL
authors.lastname: Song
authors.forename: Zhong Yang
authors.initials: ZY
authors.lastname: Shen
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery*; D016009:Chi-Square Distribution; D002681:China; D046148:Donor Selection; D005234:Fatty Liver / Q000150:complications* / Q000175:diagnosis; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D065626:Non-alcoholic Fatty Liver Disease; D016016:Proportional Hazards Models; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors / Q000600:supply & distribution*; D016896:Treatment Outcome; D055815:Young Adult